Innate Pharma S.A. reported its full‑year 2025 financial results, posting a net loss of €49.2 million, a slight improvement over the €49.5 million loss reported in 2024. The company’s cash balance at year‑end December 31 2025 was €44.8 million, down from €56.4 million at the end of September 2025, reflecting the company’s ongoing burn rate.
Total revenue for 2025 was €9.01 million, a decline from €20.1 million in 2024. The drop is largely attributable to the completion of milestone payments from its collaboration and licensing agreements with AstraZeneca and Sanofi, which reduced the recognition of proceeds in the current year. Revenue for the first nine months of 2025 was €2.3 million, compared with €4.9 million reported in the original article.
Operating expenses for the year were €63 million, a 12.1 % decrease from the previous year, driven by a 16 % reduction in research and development spending to €43.6 million. The company’s R&D cost cut was achieved through study maturity and lower indirect costs, rather than a 29 % reduction as previously stated.
Innate’s cash runway extends through the third quarter of 2026, a period that the company has highlighted as critical for achieving key clinical milestones. The workforce reduction of 30 % was completed in the first half of 2026, lowering future burn rates and aligning resources with the company’s narrowed pipeline of three high‑value assets: IPH4502, lacutamab, and monalizumab.
Key clinical milestones are scheduled for the first half of 2026: lacutamab’s confirmatory Phase III TELLOMAK‑3 trial is expected to initiate in the second half of 2026, contingent on financing, while IPH4502 dose‑escalation data are anticipated in the first half of 2026. The company’s CEO, Jonathan Dickinson, noted that “2025 has been a year of strong execution across our portfolio,” underscoring the disciplined approach to cost management and pipeline prioritization.
Analysts have responded positively to the earnings release. BTIG initiated coverage with a Buy rating and a $8 price target, while H.C. Wainwright upgraded the company to Buy from Neutral with a $5 target, reflecting confidence in the company’s strategic focus and upcoming clinical catalysts.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.